Main Menu

Publications

Types of Publications


Journal Articles

He, Y.J., Winham, S.J., Hoskins, J.M., Glass, S., Paul, J., Brown, R., Motsinger-Reif, A. & McLeod, H.L. (2016). Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial. The pharmacogenomics journal, Vol.16(3), pp. 243-248.  show abstract

Bonito, N.A., Borley, J., Wilhelm-Benartzi, C.S., Ghaem-Maghami, S. & Brown, R. (2016). Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer. Clinical cancer research, Vol.22(12), pp. 3097-3104.  show abstract

Flanagan, J.M., Brook, M.N., Orr, N., Tomczyk, K., Coulson, P., Fletcher, O., Jones, M.E., Schoemaker, M.J., Ashworth, A., Swerdlow, A., et al. (2015). Temporal Stability and Determinants of White Blood Cell DNA Methylation in the Breakthrough Generations Study. Cancer epidemiology biomarkers & prevention, Vol.24(1), pp. 221-229.  show abstract

Flower, K.J., Shenker, N.S., El-Bahrawy, M., Goldgar, D.E., Parsons, M.T., Spurdle, A.B., Morris, J.R., Brown, R. & Flanagan, J.M. (2015). DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer. Epigenetics, Vol.10(12), pp. 1121-1132.  show abstract  full text

Borley, J. & Brown, R. (2015). Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer. Annals of medicine, Vol.47(5), pp. 359-369.  show abstract

Curry, E., Green, I., Chapman-Rothe, N., Shamsaei, E., Kandil, S., Cherblanc, F.L., Payne, L., Bell, E., Ganesh, T., Srimongkolpithak, N., et al. (2015). Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells. Clinical epigenetics, Vol.7(1), p. 84.  show abstract  full text

Shenker, N.S., Flower, K.J., Wilhelm-Benartzi, C.S., Dai, W., Bell, E., Gore, E., El Bahrawy, M., Weaver, G., Brown, R. & Flanagan, J.M., et al. (2015). Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues. Bmc cancer, Vol.15(1), p. 337.  show abstract  full text

Patch, A.-., Christie, E.L., Etemadmoghadam, D., Garsed, D.W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P.J., et al. (2015). Whole–genome characterization of chemoresistant ovarian cancer. Nature, Vol.521(7553), pp. 489-494.  show abstract

Charbonneau, B., Moysich, K.B., Kalli, K.R., Oberg, A.L., Vierkant, R.A., Fogarty, Z.C., Block, M.S., Maurer, M.J., Goergen, K.M., Fridley, B.L., et al. (2014). Large-Scale Evaluation of Common Variation in Regulatory T Cell-Related Genes and Ovarian Cancer Outcome. Cancer immunology research, Vol.2(4), pp. 332-340.  show abstract

Block, M.S., Charbonneau, B., Vierkant, R.A., Fogarty, Z., Bamlet, W.R., Pharoah, P.D., Rossing, M.A., Cramer, D., Pearce, C.L., Schildkraut, J., et al. (2014). Variation in NF- B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer epidemiology biomarkers & prevention, Vol.23(7), pp. 1421-1427.  show abstract

Charbonneau, B., Block, M.S., Bamlet, W.R., Vierkant, R.A., Kalli, K.R., Fogarty, Z., Rider, D.N., Sellers, T.A., Tworoger, S.S., Poole, E., et al. (2014). Risk of Ovarian Cancer and the NF- B Pathway: Genetic Association with IL1A and TNFSF10. Cancer research, Vol.74(3), pp. 852-861.  show abstract

Earp, M.A., Kelemen, L.E., Magliocco, A.M., Swenerton, K.D., Chenevix-Trench, G., Lu, Y., Hein, A., Ekici, A.B., Beckmann, M.W., Fasching, P.A., et al. (2014). Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human genetics, Vol.133(5), pp. 481-497.  show abstract

van der Wijst, M.G., Brown, R. & Rots, M.G. (2014). Nrf2, the master redox switch: The Achilles' heel of ovarian cancer?. Biochimica et biophysica acta (bba) - reviews on cancer, Vol.1846(2), pp. 494-509.  show abstract

Glasspool, R.M., Brown, R., Gore, M.E., Rustin, G.J., McNeish, I.A., Wilson, R.H., Pledge, S., Paul, J., Mackean, M., Hall, G.D., et al. (2014). A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. British journal of cancer, Vol.110(8), pp. 1923-1929.  show abstract  full text

Huang, H., Benzonana, L.L., Zhao, H., Watts, H.R., Perry, N.J., Bevan, C., Brown, R. & Ma, D. (2014). Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination. British journal of cancer, Vol.111(7), pp. 1338-1349.  show abstract  full text

Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C.S. & Borley, J. (2014). Poised epigenetic states and acquired drug resistance in cancer. Nature reviews cancer, Vol.14(11), pp. 747-753.  show abstract

Hall, J.A. & Brown, R. (2013). Developing translational research infrastructure and capabilities associated with cancer clinical trials. Expert reviews in molecular medicine, Vol.15, p. e11.  show abstract

Sriraksa, R., Zeller, C., Dai, W., Siddiq, A., Walley, A.J., Limpaiboon, T. & Brown, R. (2013). Aberrant DNA Methylation at Genes Associated with a Stem Cell-like Phenotype in Cholangiocarcinoma Tumors. Cancer prevention research, Vol.6(12), pp. 1348-1355.  show abstract

Shenker, N.S., Polidoro, S., van Veldhoven, K., Sacerdote, C., Ricceri, F., Birrell, M.A., Belvisi, M.G., Brown, R., Vineis, P. & Flanagan, J.M., et al. (2013). Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Human molecular genetics, Vol.22(5), pp. 843-851.  show abstract

White, K.L., Vierkant, R.A., Fogarty, Z.C., Charbonneau, B., Block, M.S., Pharoah, P.D., Chenevix-Trench, G., Rossing, M.A., Cramer, D.W., Pearce, C.L., et al. (2013). Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer epidemiology biomarkers & prevention, Vol.22(5), pp. 987-992.  show abstract

Zeller, C., Dai, W., Curry, E., Siddiq, A., Walley, A., Masrour, N., Kitsou-Mylona, I., Anderson, G., Ghaem-Maghami, S., Brown, R., et al. (2013). The DNA Methylomes of Serous Borderline Tumors Reveal Subgroups With Malignant- or Benign-Like Profiles. The american journal of pathology, Vol.182(3), pp. 668-677.  show abstract

Stemke-Hale, K., Shipman, K., Kitsou-Mylona, I., de Castro, D.G., Hird, V., Brown, R., Flanagan, J., Gabra, H., Mills, G.B., Agarwal, R., et al. (2013). Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes. Modern pathology, Vol.26(4), pp. 544-552.  show abstract

Borley, J., Ghaem-Maghami, S. & Brown, R. (2013). Hypomethylation of MSX1 is associated with decreased gene expression, poor progression free survival and chemotherapy resistance in serous ovarian cancer. Bjog-an international journal of obstetrics and gynaecology, Vol.120, pp. 249-249.

Shenker, N.S., Ueland, P.M., Polidoro, S., van Veldhoven, K., Ricceri, F., Brown, R., Flanagan, J.M. & Vineis, P. (2013). DNA Methylation as a Long-term Biomarker of Exposure to Tobacco Smoke. Epidemiology, Vol.24(5), pp. 712-716.  show abstract

Johnatty, S.E., Beesley, J., Gao, B., Chen, X., Lu, Y., Law, M.H., Henderson, M.J., Russell, A.J., Hedditch, E.L., Emmanuel, C., et al. (2013). ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecologic oncology, Vol.131(1), pp. 8-14.  show abstract

Flanagan, J.M., Wilhelm-Benartzi, C.S., Metcalf, M., Kaye, S.B. & Brown, R. (2013). Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients. Annals of oncology, Vol.24(11), pp. 2813-2818.  show abstract

Cherblanc, F.L., Chapman, K.L., Reid, J., Borg, A.J., Sundriyal, S., Alcazar-Fuoli, L., Bignell, E., Demetriades, M., Schofield, C.J., DiMaggio, P.A., et al. (2013). On the Histone Lysine Methyltransferase Activity of Fungal Metabolite Chaetocin. Journal of medicinal chemistry, Vol.56(21), pp. 8616-8625.  show abstract

McWhinney-Glass, S., Winham, S.J., Hertz, D.L., Yen Revollo, J., Paul, J., He, Y., Brown, R., Motsinger-Reif, A.A. & McLeod, H.L. (2013). Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity. Clinical cancer research, Vol.19(20), pp. 5769-5776.  show abstract

Cherblanc, F.L., Chapman, K.L., Brown, R. & Fuchter, M.J. (2013). Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases. Nature chemical biology, Vol.9(3), pp. 136-137.

Dai, W., Zeller, C., Masrour, N., Siddiqui, N., Paul, J. & Brown, R. (2013). Promoter CpG Island Methylation of Genes in Key Cancer Pathways Associates with Clinical Outcome in High-Grade Serous Ovarian Cancer. Clinical cancer research, Vol.19(20), pp. 5788-5797.  show abstract

Wilhelm-Benartzi, C.S., Koestler, D.C., Karagas, M.R., Flanagan, J.M., Christensen, B.C., Kelsey, K.T., Marsit, C.J., Houseman, E.A. & Brown, R. (2013). Review of processing and analysis methods for DNA methylation array data. British journal of cancer, Vol.109(6), pp. 1394-1402.  show abstract  full text

Chapman-Rothe, N., Curry, E., Zeller, C., Liber, D., Stronach, E., Gabra, H., Ghaem-Maghami, S. & Brown, R. (2013). Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells. Oncogene, Vol.32(38), pp. 4586-4592.  show abstract

Shen, H., Fridley, B.L., Song, H., Lawrenson, K., Cunningham, J.M., Ramus, S.J., Cicek, M.S., Tyrer, J., Stram, D., Larson, M.C., et al. (2013). Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature communications, Vol.4, pp. 1628-1628.  show abstract

Permuth-Wey, J., Lawrenson, K., Shen, H.C., Velkova, A., Tyrer, J.P., Chen, Z., Lin, H.-., Ann Chen, Y., Tsai, Y.-., Qu, X., et al. (2013). Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21 31. Nature communications, Vol.4, pp. 1627-1627.  show abstract  full text

Bojesen, S.E., Pooley, K.A., Johnatty, S.E., Beesley, J., Michailidou, K., Tyrer, J.P., Edwards, S.L., Pickett, H.A., Shen, H.C., Smart, C.E., et al. (2013). Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature genetics, Vol.45(4), pp. 371-384.  show abstract

Pharoah, P.D., Tsai, Y.-., Ramus, S.J., Phelan, C.M., Goode, E.L., Lawrenson, K., Buckley, M., Fridley, B.L., Tyrer, J.P., Shen, H., et al. (2013). GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature genetics, Vol.45(4), pp. 362-370.  show abstract  full text

Thathia, S.H., Ferguson, S., Gautrey, H.E., van Otterdijk, S.D., Hili, M., Rand, V., Moorman, A.V., Meyer, S., Brown, R. & Strathdee, G., et al. (2012). Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica, Vol.97(3), pp. 371-378.  show abstract

Brennan, K., Garcia-Closas, M., Orr, N., Fletcher, O., Jones, M., Ashworth, A., Swerdlow, A., Thorne, H., Riboli, E., Vineis, P., et al. (2012). Intragenic ATM Methylation in Peripheral Blood DNA as a Biomarker of Breast Cancer Risk. Cancer research, Vol.72(9), pp. 2304-2313.  show abstract

Cherblanc, F., Chapman-Rothe, N., Brown, R. & Fuchter, M.J. (2012). Current limitations and future opportunities for epigenetic therapies. Future medicinal chemistry, Vol.4(4), pp. 425-446.  show abstract

Brown, R., Kerr, K., Haoudi, A. & Darzi, A. (2012). Tackling cancer burden in the Middle East: Qatar as an example. The lancet oncology, Vol.13(11), pp. e501-e508.  show abstract

Mac Partlin, M., Homer, E., Robinson, H., McCormick, C.J., Crouch, D.H., Durant, S.T., Matheson, E.C., Hall, A.G., Gillespie, D.A. & Brown, R., et al. (2012). Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX. Oncogene, Vol.22(6), pp. 819-825.  show abstract

Zeller, C., Dai, W., Steele, N.L., Siddiq, A., Walley, A.J., Wilhelm-Benartzi, C.S., Rizzo, S., van der Zee, A., Plumb, J. & Brown, R., et al. (2012). Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene, Vol.31(42), pp. 4567-4576.  show abstract

Borley, J., Wilhelm-Benartzi, C., Brown, R. & Ghaem-Maghami, S. (2012). Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. British journal of cancer, Vol.107(7), pp. 1069-1074.  show abstract  full text

Goode, E.L., Chenevix-Trench, G., Hartmann, L.C., Fridley, B.L., Kalli, K.R., Vierkant, R.A., Larson, M.C., White, K.L., Keeney, G.L., Oberg, T.N., et al. (2011). Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality. Cancer epidemiology biomarkers & prevention, Vol.20(8), pp. 1638-1648.  show abstract

Pharoah, P.D., Palmieri, R.T., Ramus, S.J., Gayther, S.A., Andrulis, I.L., Anton-Culver, H., Antonenkova, N., Antoniou, A.C., Goldgar, D., Beattie, M.S., et al. (2011). The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clin cancer res, Vol.17(11), pp. 3742-3750.  show abstract

Stronach, E.A., Alfraidi, A., Rama, N., Datler, C., Studd, J.B., Agarwal, R., Guney, T.G., Gourley, C., Hennessy, B.T., Mills, G.B., et al. (2011). HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer. Cancer res, Vol.71(13), pp. 4412-4422.  show abstract

Rizzo, S., Hersey, J.M., Mellor, P., Dai, W., Santos-Silva, A., Liber, D., Luk, L., Titley, I., Carden, C.P., Box, G., et al. (2011). Ovarian Cancer Stem Cell-Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2. Molecular cancer therapeutics, Vol.10(2), pp. 325-335.  show abstract

Steele, N.L., Plumb, J.A., Vidal, L., Tjornelund, J., Knoblauch, P., Buhl-Jensen, P., Molife, R., Brown, R., de Bono, J.S. & Evans, T.R., et al. (2011). Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer chemoth pharm, Vol.67(6), pp. 1273-1279.  show abstract

Sriraksa, R., Zeller, C., El-Bahrawy, M.A., Dai, W., Daduang, J., Jearanaikoon, P., Chau-in, S., Brown, R. & Limpaiboon, T. (2011). CpG-island methylation study of liver fluke-related cholangiocarcinoma. British journal of cancer, Vol.104(8), pp. 1313-1318.  show abstract  full text

Huang, R.S., Johnatty, S.E., Gamazon, E.R., Im, H.K., Ziliak, D., Duan, S., Zhang, W., Kistner, E.O., Chen, P., Beesley, J., et al. (2011). Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients. Clinical cancer research, Vol.17(16), pp. 5490-5500.  show abstract

Dai, W., Teodoridis, J.M., Zeller, C., Graham, J., Hersey, J., Flanagan, J.M., Stronach, E., Millan, D.W., Siddiqui, N., Paul, J., et al. (2011). Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival. Clin cancer res, Vol.17(12), pp. 4052-4062.  show abstract

Amankwah, E.K., Wang, Q., Schildkraut, J.M., Tsai, Y.-., Ramus, S.J., Fridley, B.L., Beesley, J., Johnatty, S.E., Webb, P.M., Chenevix-Trench, G., et al. (2011). Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium. Plos one, Vol.6(5), pp. e19642-e19642.  show abstract  full text

Chapman-Rothe, N. & Brown, R. (2011). PROSPECTS FOR EPIGENETIC COMPOUNDS IN THE TREATMENT OF AUTOIMMUNE DISEASE. Adv exp med biol, Vol.711, pp. 150-161.  show abstract

Zeller, C. & Brown, R. (2010). Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer. Therapeutic advances in medical oncology, Vol.2(5), pp. 319-329.  show abstract

Paige, A.J., Zucknick, M., Janczar, S., Paul, J., Mein, C.A., Taylor, K.J., Stewart, M., Gourley, C., Richardson, S., Perren, T., et al. (2010). WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis. Eur j cancer, Vol.46(4), pp. 818-825.  show abstract

Strathdee, G., Ferguson, S., Sim, A. & Brown, R. (2010). DNA methylation does not regulate JUNB expression in CML: Comment on “Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia” by Hoshino et al [Leuk Res 33 (2009) 1361–1366]. Leukemia research, Vol.34(5), pp. 685-686.  show abstract

Bolton, K.L., Tyrer, J., Song, H., Ramus, S.J., Notaridou, M., Jones, C., Sher, T., Gentry-Maharaj, A., Wozniak, E., Tsai, Y.-., et al. (2010). Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature genetics, Vol.42(10), pp. 880-884.  show abstract  full text

Steele, N., Finn, P., Brown, R. & Plumb, J.A. (2009). Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Brit j cancer, Vol.100(5), pp. 758-763.  show abstract  full text

Graham, J.S., Kaye, S.B. & Brown, R. (2009). The promises and pitfalls of epigenetic therapies in solid tumours. European journal of cancer, Vol.45(7), pp. 1129-1136.  show abstract

Scott, L.C., Evans, T.R., Cassidy, J., Harden, S., Paul, J., Ullah, R., O'Brien, V. & Brown, R. (2009). Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. Brit j cancer, Vol.101(3), pp. 410-417.  show abstract  full text

Chapman-Rothe, N. & Brown, R. (2009). Approaches to target the genome and its epigenome in cancer. Future med chem, Vol.1(8), pp. 1481-1495.  show abstract

Lin, (2009). Identification of candidate epigenetic biomarkers for ovarian cancer detection. Oncology reports, Vol.22(4), pp. 853-861.  show abstract

Johnatty, S.E., Beesley, J., Paul, J., Fereday, S., Spurdle, A.B., Webb, P.M., Byth, K., Marsh, S., McLeod, H., Harnett, P.R., et al. (2008). ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy. Clinical cancer research, Vol.14(17), pp. 5594-5601.  show abstract

Marsh, S., Paul, J., McLeod, H.L. & Brown, R. (2008). Ethnic considerations in pharmacogenetic studies - In reply. Journal of clinical oncology, Vol.26(10), pp. 1767-1768.

Steele, N.L., Plumb, J.A., Vidal, L., Tjornelund, J., Knoblauch, P., Rasmussen, A., Ooi, C.E., Buhl-Jensen, P., Brown, R., Evans, T.R., et al. (2008). A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clinical cancer research, Vol.14(3), pp. 804-810.  show abstract

Dai, W., Teodoridis, J.M., Graham, J., Zeller, C., Huang, T.H., Yan, P., Vass, J.K., Brown, R. & Paul, J. (2008). Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands. Bmc bioinformatics, Vol.9(1),  show abstract  full text

Paul, J., Marsh, S., McLeod, H.L. & Brown, R. (2008). No evidence for taxane/platinum pharmacogenetic markers: Just lack of power? Reply. Journal of clinical oncology, Vol.26(11), pp. 1904-1905.

Paige, A.J. & Brown, R. (2008). Pharmaco(epi)genomics in ovarian cancer. Pharmacogenomics, Vol.9(12), pp. 1825-1834.  show abstract

Teodoridis, J.M., Hardie, C. & Brown, R. (2008). CpG island methylator phenotype (CIMP) in cancer: Causes and implications. Cancer lett, Vol.268(2), pp. 177-186.  show abstract

Strathdee, G., Holyoake, T.L., Sim, A., Parker, A., Oscier, D.G., Melo, J.V., Meyer, S., Eden, T., Dickinson, A.M., Mountford, J.C., et al. (2007). Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor Prognosis. Clinical cancer research, Vol.13(17), pp. 5048-5055.  show abstract

Strathdee, G., Sim, A., Soutar, R., Holyoake, T.L. & Brown, R. (2007). HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia. Carcinogenesis, Vol.28(2), pp. 299-309.  show abstract

Hall, J.A., Brown, R. & Paul, J. (2007). An exploration into study design for biomarker identification: issues and recommendations. Cancer genomics & proteomics, Vol.4(3), pp. 111-119.  show abstract

Epping, M.T., Wang, L., Plumb, J.A., Lieb, M., Gronemeyer, H., Brown, R. & Bernards, R. (2007). A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proceedings of the national academy of sciences, Vol.104(45), pp. 17777-17782.  show abstract

Marsh, S., Paul, J., King, C.R., Gifford, G., McLeod, H.L. & Brown, R. (2007). Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer. Journal of clinical oncology, Vol.25(29), pp. 4528-4535.  show abstract

Brown, R. & Glasspool, R. (2007). Epigenetic modulation of resistance to chemotherapy?. Annals of oncology, Vol.18(9), pp. 1429-1430.  show abstract

Robinson, H., Bratlie-Thoresen, S., Brown, R. & Gillespie, D.A. (2007). Chk1 is required for G2/M Checkpoint Response Induced by the Catalytic Topoisomerase II Inhibitor ICRF-193. Cell cycle, Vol.6(10), pp. 1265-1267.  show abstract

Robinson, H.M., Black, E.J., Brown, R. & Gillespie, D.A. (2007). DNA mismatch repair and Chk1-dependent centrosome amplification in response to DNA alkylation damage. Cell cycle, Vol.6(8), pp. 982-992.  show abstract

Ordway, J.M., Budiman, M.A., Korshunova, Y., Maloney, R.K., Bedell, J.A., Citek, R.W., Bacher, B., Peterson, S., Rohlfing, T., Hall, J., et al. (2007). Identification of Novel High-Frequency DNA Methylation Changes in Breast Cancer. Plos one, Vol.2(12), pp. e1314-e1314.  show abstract  full text

de Graeff, P., Hall, J., Crijns, A.P., de Bock, G.H., Paul, J., ten Hoor, K.A., de Jong, S., Hollema, H., Bartlett, J.M., Brown, R., et al. (2007). Reply: The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer. British journal of cancer, Vol.96(10), pp. 1623-1624.

Marsh, S. (2006). ABCB1 2677G>T/A Genotype and Paclitaxel Pharmacogenetics in Ovarian Cancer. Clinical cancer research, Vol.12(13), pp. 4127-4129.  show abstract

Wei, S.H. (2006). Prognostic DNA Methylation Biomarkers in Ovarian Cancer. Clinical cancer research, Vol.12(9), pp. 2788-2794.  show abstract

de Graeff, P., Hall, J., Crijns, A.P., de Bock, G.H., Paul, J., Oien, K.A., ten Hoor, K.A., de Jong, S., Hollema, H., Bartlett, J.M., et al. (2006). Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. British journal of cancer, Vol.95(5), pp. 627-633.  show abstract  full text

O'Brien, V. & Brown, R. (2006). Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis, Vol.27(4), pp. 682-692.  show abstract

Strathdee, G., Sim, A., Parker, A., Oscier, D. & Brown, R. (2006). Promoter hypermethylation silences expression of the HoxA4 gene and correlates with IgVh mutational status in CLL. Leukemia, Vol.20(7), pp. 1326-1329.  show abstract

Robinson, H.M., Jones, R., Walker, M., Zachos, G., Brown, R., Cassidy, J. & Gillespie, D.A. (2006). Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene, Vol.25(39), pp. 5359-5369.  show abstract

Smith, L.V., Parenty, A.D., Guthrie, K.M., Plumb, J., Brown, R. & Cronin, L. (2006). Dihydroimidazophenanthridinium (DIP)-based DNA binding agents with tuneable structures and biological activity. Chembiochem, Vol.7(11), pp. 1757-1763.  show abstract

Giotopoulos, G., McCormick, C., Cole, C., Zanker, A., Jawad, M., Brown, R. & Plumb, M. (2006). DNA methylation during mouse hemopoietic differentiation and radiation-induced leukemia. Experimental hematology, Vol.34(11), pp. 1462-1470.  show abstract

Lindsey, J.C., Lusher, M.E., Strathdee, G., Brown, R., Gilbertson, R.J., Bailey, S., Ellison, D.W. & Clifford, S.C. (2006). Epigenetic inactivation ofMCJ (DNAJD1) in malignant paediatric brain tumours. International journal of cancer, Vol.118(2), pp. 346-352.  show abstract

Glasspool, R.M., Teodoridis, J.M. & Brown, R. (2006). Epigenetics as a mechanism driving polygenic clinical drug resistance. Brit j cancer, Vol.94(8), pp. 1087-1092.  show abstract  full text

Steele, N., Vidal, L., Plumb, J., Attard, G., Rasmussen, A., Buhl-Jensen, P., Brown, R., Blagden, S., Evans, J. & de Bono, J., et al. (2005). A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours. Journal of clinical oncology, Vol.23(16), pp. 200S-200S.  show abstract

Gallagher, W.M. (2005). Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis, Vol.26(11), pp. 1856-1867.  show abstract

Teodoridis, J.M., Hall, J., Marsh, S., Kannall, H.D., Smyth, C., Curto, J., Siddiqui, N., Gabra, H., McLeod, H.L., Strathdee, G., et al. (2005). CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer res, Vol.65(19), pp. 8961-8967.  show abstract

Strathdee, G., Vass, J.K., Oien, K.A., Siddiqui, N., Curto-Garcia, J. & Brown, R. (2005). Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol oncol, Vol.97(3), pp. 898-903.  show abstract

Pors, K., Plumb, J.A., Brown, R., Teesdale-Spittle, P., Searcey, M., Smith, P.J. & Patterson, L.H. (2005). Development of Nonsymmetrical 1,4-Disubstituted Anthraquinones That Are Potently Active against Cisplatin-Resistant Ovarian Cancer Cells. Journal of medicinal chemistry, Vol.48(21), pp. 6690-6695.  show abstract

Parenty, A.D., Smith, L.V., Guthrie, K.M., Long, D.L., Plumb, J., Brown, R. & Cronin, L. (2005). Highly stable phenanthridinium frameworks as a new class of tunable DNA binding agents with cytotoxic properties. J med chem, Vol.48(14), pp. 4504-4506.  show abstract

Chan, M.W. (2005). Hypermethylation of 18S and 28S Ribosomal DNAs Predicts Progression-Free Survival in Patients with Ovarian Cancer. Clinical cancer research, Vol.11(20), pp. 7376-7383.  show abstract

Lyko, F. & Brown, R. (2005). DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies. Jnci journal of the national cancer institute, Vol.97(20), pp. 1498-1506.  show abstract

Gifford, G. (2004). The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients. Clinical cancer research, Vol.10(13), pp. 4420-4426.  show abstract

Morley, S. (2004). The dl1520 Virus Is Found Preferentially in Tumor Tissue after Direct Intratumoral Injection in Oral Carcinoma. Clinical cancer research, Vol.10(13), pp. 4357-4362.  show abstract

Gifford, G. & Brown, R. (2004). Microsatellite instability: theory and methods. Methods in molecular medicine, Vol.97, pp. 237-250.  show abstract

Barvaux, V.A., Ranson, M., Brown, R., McElhinney, R.S., McMurry, T.B. & Margison, G.P. (2004). Dual repair modulation reverses Temozolomide resistance in vitro. Molecular cancer therapeutics, Vol.3(2), pp. 123-127.  show abstract

Strathdee, G., Davies, B.R., Vass, J.K., Siddiqui, N. & Brown, R. (2004). Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene. Carcinogenesis, Vol.25(5), pp. 693-701.  show abstract

Hall, J., Paul, J. & Brown, R. (2004). Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert reviews in molecular medicine, Vol.6(12), pp. 1-20.  show abstract

Brown, R. & Plumb, J.A. (2004). Demethylation of DNA by decitabine in cancer chemotherapy. Expert review of anticancer therapy, Vol.4(4), pp. 501-510.  show abstract

Teodoridis, J.M., Strathdee, G. & Brown, R. (2004). Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug resist update, Vol.7(4-5), pp. 267-278.  show abstract

Strathdee, G. & Brown, R. (2004). Bioscience 2004. Pharmacogenomics, Vol.5(7), pp. 775-778.  show abstract

Balch, C., Huang, T.H., Brown, R. & Nephew, K.P. (2004). The epigenetics of ovarian cancer drug resistance and resensitization. American journal of obstetrics and gynecology, Vol.191(5), pp. 1552-1572.  show abstract

Strathdee, G., Sim, A. & Brown, R. (2004). Control of gene expression by CpG island methylation in normal cells. Biochem soc t, Vol.32(6), pp. 913-915.  show abstract

Teodoridis, J.M., Strathdee, G., Plumb, J.A. & Brown, R. (2004). CpG-island methylation and epigenetic control of resistance to chemotherapy. Biochem soc t, Vol.32(6), pp. 916-917.  show abstract

Plumb, J.A., Steele, N., Finn, P.W. & Brown, R. (2004). Epigenetic approaches to cancer therapy. Biochemical society transactions, Vol.32(6), pp. 1095-1097.  show abstract

Plumb, J.A., Finn, P.W., Williams, R.J., Bandara, M.J., Romero, M.R., Watkins, C.J., La Thangue, N.B. & Brown, R. (2003). Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol cancer ther, Vol.2(8), pp. 721-728.  show abstract

Kim, Y.T., Ganly, I., Brown, R. & Stuart, D. (2003). Acquired resistance to cytolysis of the E1B-attenuated adenovirus, dl1520, in ovarian tumour cell lines. Cancer gene therapy, Vol.10(8), pp. 589-590.  show abstract

Song, J.S., Kim, S.B., Lee, Y.H., Lee, K.W., Jung, H.H., Kim, M.H., Kim, K.T., Brown, R. & Kim, Y.T. (2002). Adenovirus-mediated antisense expression of telomerase template RNA induces apoptosis in lung cancer cells. Journal of microbiology and biotechnology, Vol.12(1), pp. 89-95.  show abstract

Strathdee, G. & Brown, R. (2002). Aberrant DNA methylation in cancer: potential clinical interventions. Expert reviews in molecular medicine, Vol.4(04), pp. 1-17.  show abstract

Strathdee, G. & Brown, R. (2002). Epigenetic cancer therapies: DNA methyltransferase inhibitors. Expert opin inv drug, Vol.11(6), pp. 747-754.  show abstract

Wei, S.H., Chen, C.M., Strathdee, G., Harnsomburana, J., Shyu, C.R., Rahmatpanah, F., Shi, H.D., Ng, S.W., Yan, P.S., Nephew, K.P., et al. (2002). Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clinical cancer research, Vol.8(7), pp. 2246-2252.  show abstract

Brown, R. & Strathdee, G. (2002). Epigenomics and epigenetic therapy of cancer. Trends mol med, Vol.8(4), pp. S43-S48.  show abstract

Hirst, G.L. & Brown, R. (2001). Detection of the Replication Error Phenotype in Ovarian Cancer-PCR Analysis of Microsatellite Instability. Methods in molecular medicine, Vol.39, pp. 375-382.  show abstract

Brown, R., Smith, W.E. & Graham, D. (2001). Synthesis of a benzotriazole phosphoramidite for attachment of oligonucleotides to metal surfaces. Tetrahedron letters, Vol.42(11), pp. 2197-2200.  show abstract

Strathdee, G., Appleton, K., Illand, M., Millan, D.W., Sargent, J., Paul, J. & Brown, R. (2001). Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am j pathol, Vol.158(3), pp. 1121-1127.  show abstract

Ganly, I., Kim, Y.T., Hann, B., Balmain, A. & Brown, R. (2001). Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis. Gene ther, Vol.8(5), pp. 369-375.  show abstract

Strathdee, G., Sansom, O.J., Sim, A., Clarke, A.R. & Brown, R. (2001). A role for mismatch repair in control of DNA ploidy following DNA damage. Oncogene, Vol.20(15), pp. 1923-1927.  show abstract

Stuart, D., Khan, Q.A., Brown, R. & Dipple, A. (2001). Hydrocarbon carcinogens induce p53 activity in normal mouse tissue. Cancer lett, Vol.173(2), pp. 111-114.  show abstract

Plumb, J.A., Strathdee, G., Sludden, J., Kaye, S.B. & Brown, R. (2000). Reversal of drug resistance in human tumor xenografts by 2 '-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer res, Vol.60(21), pp. 6039-6044.  show abstract

Mackay, H.J., Cameron, D., Rahilly, M., Mackean, M.J., Paul, J., Kaye, S.B. & Brown, R. (2000). Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J clin oncol, Vol.18(1), pp. 87-93.  show abstract

Ganly, I., Soutar, D.S., Brown, R. & Kaye, S.B. (2000). p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy. Brit j cancer, Vol.82(2), pp. 392-398.  show abstract  full text

Heise, C., Ganly, I., Kim, Y.T., Sampson-Johannes, A., Brown, R. & Kirn, D. (2000). Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene therapy, Vol.7(22), pp. 1925-1929.  show abstract

Moreland, N.J., Illand, M., Kim, Y.T., Paul, J. & Brown, R. (1999). Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer res, Vol.59(9), pp. 2102-2106.  show abstract

Gallagher, W.M. & Brown, R. (1999). p53-oriented cancer therapies: Current progress. Annals of oncology, Vol.10(2), pp. 139-150.  show abstract

Strathdee, G., MacKean, M.J., Illand, M. & Brown, R. (1999). A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene, Vol.18(14), pp. 2335-2341.  show abstract

Brown, R. & Links, M. (1999). Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert reviews in molecular medicine, Vol.1(15), pp. 1-21.  show abstract

Durant, S.T., Morris, M.M., Illand, M., McKay, H.J., McCormick, C., Hirst, G.L., Borts, R.H. & Brown, R. (1999). Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr biol, Vol.9(1), pp. 51-54.  show abstract

Colella, G., Marchini, S., D’Incalci, M., Brown, R. & Broggini, M. (1999). Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. British journal of cancer, Vol.80(3-4), pp. 338-343.  show abstract  full text

Jones, N.A., Turner, J., McIlwrath, A.J., Brown, R. & Dive, C. (1998). Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between Bax and Bak up-regulation and the functional status of p53. Molecular pharmacology, Vol.53(5), pp. 819-826.  show abstract

McDonald, A.C. & Brown, R. (1998). Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. Brit j cancer, Vol.78(6), pp. 745-751.  show abstract  full text

Veldhoen, N., Stewart, J., Brown, R. & Milner, J. (1998). Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog. Oncogene, Vol.16(2), pp. 249-255.  show abstract

Yamada, M. (1997). Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic acids research, Vol.25(3), pp. 491-496.  show abstract

Brown, R., Hirst, G.L., Gallagher, W.M., McIlwrath, A.J., Margison, G.P., vanderZee, A.G. & Anthoney, D.A. (1997). hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene, Vol.15(1), pp. 45-52.  show abstract

Gallagher, W.M., Cairney, M., Schott, B., Roninson, I.B. & Brown, R. (1997). Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene, Vol.14(2), pp. 185-193.  show abstract

McIlwrath, A.J., Brunton, V.G. & Brown, R. (1996). Cell-cycle arrests and p53 accumulation induced by geldanamycin in human ovarian tumour cells. Cancer chemoth pharm, Vol.37(5), pp. 423-428.  show abstract

Vasey, P.A., Jones, N.A., Jenkins, S., Dive, C. & Brown, R. (1996). Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol pharmacol, Vol.50(6), pp. 1536-1540.  show abstract

Anthoney, D.A., McIlwrath, A.J., Gallagher, W.M., Edlin, A.R. & Brown, R. (1996). Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer res, Vol.56(6), pp. 1374-1381.  show abstract

Drummond, J.T., Anthoney, A., Brown, R. & Modrich, P. (1996). Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line. Journal of biological chemistry, Vol.271(33), pp. 19645-19648.  show abstract

MURPHY, D.S., HOARE, S.F., GOING, J.J., MALLON, E.E., GEORGE, W.D., KAYE, S.B., BROWN, R., BLACK, D.M. & KEITH, W.N. (1995). CHARACTERIZATION OF EXTENSIVE GENETIC ALTERATIONS IN DUCTAL CARCINOMA IN-SITU BY FLUORESCENCE IN-SITU HYBRIDIZATION AND MOLECULAR ANALYSIS. J natl cancer i, Vol.87(22), pp. 1694-1704.  show abstract

MURPHY, D.S., MCHARDY, P., COUTTS, J., MALLON, E.A., GEORGE, W.D., KAYE, S.B., BROWN, R. & KEITH, W.N. (1995). INTERPHASE CYTOGENETIC ANALYSIS OF ERBB2 AND TOPOII-ALPHA COAMPLIFICATION IN INVASIVE BREAST-CANCER AND POLYSOMY OF CHROMOSOME-17 IN DUCTAL CARCINOMA IN-SITU. Int j cancer, Vol.64(1), pp. 18-26.  show abstract

McLeod, H.L., Douglas, F., Oates, M., Symonds, R.P., Prakash, D., Van Der Zee, A.G., Kaye, S.B., Brown, R. & Keith, W.N. (1994). Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. International journal of cancer, Vol.59(5), pp. 607-611.  show abstract

MCLEOD, H., DOUGLAS, F., OATES, M., SYMONDS, R., PRAKASH, D., VANDERZEE, A., KAYE, S., BROWN, R. & KEITH, W. (1994). TOPOISOMERASE-I AND TOPOISOMERASE-II ACTIVITY IN HUMAN BREAST, CERVIX, LUNG AND COLON-CANCER. International journal of cancer, Vol.59(5), pp. 607-611.  show abstract

van der Zee, A.G., Vries, E.G., Hollema, H., Kaye, S.B., Brown, R. & Keith, W.N. (1994). Molecular analysis of the topoisomerase II α gene and its expression in human ovarian cancer. Annals of oncology, Vol.5(1), pp. 75-81.  show abstract

MCILWRATH, A., VASEY, P., ROSS, G. & BROWN, R. (1994). CELL-CYCLE ARRESTS AND RADIOSENSITIVITY OF HUMAN TUMOR-CELL LINES - DEPENDENCE ON WILD-TYPE P53 FOR RADIOSENSITIVITY. Cancer research, Vol.54(14), pp. 3718-3722.  show abstract

MORRISON, J.G., BISSETT, D., STEPHENS, I.F., MCKAY, K., BROWN, R., GRAHAM, M.A., FICHTINGERSCHEPMAN, A.M. & KERR, D.J. (1993). THE ISOLATION AND IDENTIFICATION OF CIS-DIAMMINEDICHLOROPLATINUM (II)-DNA ADDUCTS BY ANION-EXCHANGE HPLC AND INDUCTIVELY COUPLED PLASMA MASS-SPECTROMETRY. Int j oncol, Vol.2(1), pp. 33-37.  show abstract

BISSETT, D., MCLAUGHLIN, K., KELLAND, L.R. & BROWN, R. (1993). CISPLATIN-DNA DAMAGE RECOGNITION PROTEINS IN HUMAN TUMOR EXTRACTS. Brit j cancer, Vol.67(4), pp. 742-748.  show abstract  full text

BROWN, R. (1993). P53 - A TARGET FOR NEW ANTICANCER DRUGS OR A TARGET FOR OLD DRUGS. Ann oncol, Vol.4(8), pp. 623-629.

COUTTS, J., PLUMB, J.A., BROWN, R. & KEITH, W.N. (1993). EXPRESSION OF TOPOISOMERASE-II-ALPHA AND TOPOISOMERASE-II-BETA IN AN ADENOCARCINOMA CELL-LINE CARRYING AMPLIFIED TOPOISOMERASE-II-ALPHA AND RETINOIC ACID RECEPTOR-ALPHA GENES. Brit j cancer, Vol.68(4), pp. 793-800.  show abstract  full text

MCLAUGHLIN, K., COREN, G., MASTERS, J. & BROWN, R. (1993). BINDING ACTIVITIES OF CIS-PLATIN-DAMAGE-RECOGNITION PROTEINS IN HUMAN TUMOR-CELL LINES. Int j cancer, Vol.53(4), pp. 662-666.  show abstract

BROWN, R., CLUGSTON, C., BURNS, P., EDLIN, A., VASEY, P., VOJTESEK, B. & KAYE, S.B. (1993). INCREASED ACCUMULATION OF P53 PROTEIN IN CISPLATIN-RESISTANT OVARIAN CELL-LINES. Int j cancer, Vol.55(4), pp. 678-684.  show abstract

KEITH, W.N., DOUGLAS, F., WISHART, G.C., MCCALLUM, H.M., GEORGE, W.D., KAYE, S.B. & BROWN, R. (1993). COAMPLIFICATION OF ERBB2, TOPOISOMERASE-II-ALPHA AND RETINOIC ACID RECEPTOR-ALPHA GENES IN BREAST-CANCER AND ALLELIC LOSS AT TOPOISOMERASE-I ON CHROMOSOME-20. Eur j cancer, Vol.29A(10), pp. 1469-1475.  show abstract

Ross, G. & Brown, R. (1992). The role of DNA repair processes in determining response to cancer therapy. European journal of cancer, Vol.28(1), pp. 281-285.

KEITH, W.N., TAN, K.B. & BROWN, R. (1992). AMPLIFICATION OF THE TOPOISOMERASE-II ALPHA-GENE IN A NON-SMALL-CELL LUNG-CANCER CELL-LINE AND CHARACTERIZATION OF POLYMORPHISMS AT THE HUMAN TOPOISOMERASE-II ALPHA-LOCI AND BETA-LOCI IN NORMAL TISSUE. Gene chromosome canc, Vol.4(2), pp. 169-175.  show abstract

CLUGSTON, C.K., MCLAUGHLIN, K., KENNY, M.K. & BROWN, R. (1992). BINDING OF HUMAN SINGLE-STRANDED-DNA BINDING-PROTEIN TO DNA DAMAGED BY THE ANTICANCER DRUG CIS-DIAMMINEDICHLOROPLATINUM(II). Cancer res, Vol.52(22), pp. 6375-6379.  show abstract

BROWN, R. (1991). GENE AMPLIFICATION AND DRUG-RESISTANCE. J pathol, Vol.163(4), pp. 287-292.

KEITH, W.N. & BROWN, R. (1991). CARCINOGENESIS AND THE RESPONSE OF TUMORS TO ANTICANCER DRUGS. Anticancer res, Vol.11(5), pp. 1739-1743.  show abstract

MCLAUGHLIN, K., STEPHENS, I., MCMAHON, N. & BROWN, R. (1991). SINGLE STEP SELECTION OF CIS-DIAMMINEDICHLOROPLATINUM(II) RESISTANT MUTANTS FROM A HUMAN OVARIAN-CARCINOMA CELL-LINE. Cancer res, Vol.51(8), pp. 2242-2245.  show abstract

KEITH, W.N., MEE, P.J. & BROWN, R. (1990). RESPONSE OF MOUSE SKIN TUMORS TO DOXORUBICIN IS DEPENDENT ON CARCINOGEN EXPOSURE. Cancer res, Vol.50(21), pp. 6841-6847.  show abstract

KEITH, W.N., STALLARD, S. & BROWN, R. (1990). EXPRESSION OF MDR1 AND GST-PI IN HUMAN BREAST-TUMORS - COMPARISON TO INVITRO CHEMOSENSITIVITY. Brit j cancer, Vol.61(5), pp. 712-716.  show abstract  full text

KEITH, W.N., BROWN, R. & PRAGNELL, I.B. (1990). RETROVIRUS MEDIATED TRANSFER AND EXPRESSION OF GM-CSF IN HEMATOPOIETIC-CELLS. Brit j cancer, Vol.62(3), pp. 388-394.  show abstract  full text

MEE, P.J. & BROWN, R. (1990). CONSTRUCTION AND HORMONE REGULATION OF A NOVEL RETROVIRAL VECTOR. Gene, Vol.88(2), pp. 289-292.  show abstract

KEITH, N., MEE, P. & BROWN, R. (1989). RESPONSE OF CHEMICALLY AND VIRALLY INDUCED MOUSE SKIN TUMORS TO DOXORUBICIN. British journal of cancer, Vol.60(3), pp. 496-497.

Gow, J., Hughes, D., Farr, C., Hamblin, T., Oscier, D., Brown, R. & Padua, R.A. (1988). Activation of Ha-ras in human chronic granulocytic and chronic myelomonocytic leukaemia. Leukemia research, Vol.12(10), pp. 805-810.  show abstract


Conferences

SHENKER, N.A., Flower, K.J., Wilhelm-Benartzi, C., Dai, W., Bell, E., El Bahrawy, M., Weaver, G., Flanagan, J.M. & Brown, R. (2015). Abstract 1063: Transcriptional implications of intragenic DNA methylation in the estrogen receptor alpha gene in breast cancer cells and tissues, Cancer Research, Vol.75(15 Supplement), p.1063.

Brown, R., Timms, K., Paul, J., Hughes, E., El-Bahrawy, M., Steel, J.H., Kalva, S., Liu, X., Wang, Y., Rama, N.R., et al. (2015). Homologous recombination (HR) deficiency, tumor BRCA1/2 mutations (tmBRCA) and association with response and outcome following platinum monotherapy in high grade serous ovarian cancer (HGSOC)., JOURNAL OF CLINICAL ONCOLOGY, Vol.33(15).

Brown, R., Fuchter, M., Curry, E., Green, I., Kandil, S., Cherblanc, F., Payne, L., Chapman-Rothe, N., Shamsaei, E., Srimongkolpithak, N., et al. (2014). Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells, EUROPEAN JOURNAL OF CANCER, Vol.50, pp.179-180.

Polidoro, S., Shenker, N., van Veldhoven, K., Sacerdote, C., Ricceri, F., Critelli, R., Brown, R., Vineis, P. & Flanagan, J.M. (2012). Epigenome-wide Association Study in the European Prospective Investigation Into Cancer and Nutrition (EPIC-Turin) Identifies Novel Genes Associated With Smoking, EUROPEAN JOURNAL OF CANCER, Vol.48, pp.S124-S125.

He, Y., Wood, S.J., Paul, J., Motsinger-Reif, A., Auman, T., Hoskins, J.M., Brown, R. & McLeod, H.L. (2011). GENETIC MARKERS ASSOCIATED WITH PLATINUM/TAXANES INDUCED GASTROINTESTINAL TOXICITY IN SCOTROC1 TRIAL., CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.89, pp.S66-S67.

He, Y., Wood, S.J., Paul, J., Motsinger-Reif, A., Auman, T., Hoskins, J.M., Brown, R. & McLeod, H.L. (2011). GENETIC MARKERS ASSOCIATED WITH PLATINUM/TAXANES INDUCED GASTROINTESTINAL TOXICITY IN SCOTROC1 TRIAL, CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.89, pp.S4-S5.

Strathdee, G., Holyoake, T.L., Sim, A., Parker, A., Oscier, D.G., Melo, J.V., Meyer, S., Eden, T., Dickinson, A.M., Soutar, R., et al. (2007). HOX genes are a major target for epigenetic mis-regulation in adult and childhood leukaemia, Presented at 47th Annual Scientific Meeting of the British-Society-for-Haematology, Bournemouth, ENGLAND. BRITISH JOURNAL OF HAEMATOLOGY, Vol.137, p.81.

Appleton, K., Mackay, H.J., Judson, I., Plumb, J.A., McCormick, C., Strathdee, G., Lee, C., Barrett, S., Reade, S., Jadayel, D., et al. (2007). Phase I and Pharmacodynamic Trial of the DNA Methyltransferase Inhibitor Decitabine and Carboplatin in Solid Tumors, Presented at 17th EORTC/AACR/NCI International Conference on Molecular Targets and Cancer Therapeutics, United States. Journal of Clinical Oncology, Vol.25(29), pp.4603-4609.

Strathdee, G.R., Holyoake, T.L., Sim, A., Parker, A., Oscier, D.G., Melo, J.V., Meyer, S., Eden, T., Dickinson, A.M., Mountford, J., et al. (2007). HOX genes - Candidate tumor suppressor genes in adult, and childhood leukemia., Presented at 49th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA. BLOOD, Vol.110(11), p.777A.

White, D.J., Meyer, S., Will, A.M., Sims, A., Eden, T., Brown, R. & Strathdee, G. (2006). No evidence of significant FANCF, FANCB or NBS1 methylation in sporadic acute childhood leukaemia, Presented at 46th Annual Scientific Meetign of the British-Society-for-Haematology, Edinburgh, ENGLAND. BRITISH JOURNAL OF HAEMATOLOGY, Vol.133, p.22.

Jansen, R.A., Liu, J.C., Liyanarachchi, S., Crijns, A.P., Van, P.S., Huang, T.H., Cohn, D.E., Fowler, J.M., Van der Zee, A.G. & Brown, R., et al. (2006). Prognostic impact of MAD1L1 promoter hypermethylation in advanced ovarian cancer., Presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, Atlanta, GA. JOURNAL OF CLINICAL ONCOLOGY, Vol.24(18), p.261S.

Ordway, J.M., Leon, J., Korshunova, Y., Budiman, M.A., Hall, J., Maloney, R.K., Bedell, J.A., Citek, R.W., Jeddeloh, J.A., Brown, R., et al. (2006). New approach for genome wide scanning of differentially methylated genes reveals large list of novel and powerful biomarkers for breast cancer., Presented at 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX. BREAST CANCER RESEARCH AND TREATMENT, Vol.100, pp.S43-S44.

Lennon, A.M., Tan, A.C., Gleeson, F., Brannigan, A., Lennon, J.R., O'Sullivan, J., White, A., Keegan, D., Mulcahy, H., Hyland, J.M., et al. (2005). Proteomics: A new tool for screening for colon cancer?, Presented at Annual Meeting of the British-Society-of-Gastroenterology, Birmingham, ENGLAND. GUT, Vol.54, p.A20.

Strathdee, G., Holyoake, T.L., Sim, A., Melo, J.V., Soutar, R., Parker, A., Oscier, D.G. & Brown, R. (2005). HoxA cluster genes are frequently targeted by DNA methylation in CML and other types of human leukaemia, Presented at 34th Annual Meeting of the International-Society-for-Experimental-Hematology, Univ Glasgow, Glasgow, SCOTLAND. EXPERIMENTAL HEMATOLOGY, Vol.33(7), p.50.

Barrett, S.V., Lee, C.P., Appleton, K.J., Reade, S., Jadayel, D., Bellenger, K., Mackay, L.M., Twelves, C.J., Kaye, S.B., Judson, I.R., et al. (2005). Phase I trial of the DNA hypomethylating agent 5-aza-2 ' deoxycytidine (decitabine) in combination with carboplatin both given 4-weekly by intravenous injection in patients with advanced solid tumours., Presented at AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA. CLINICAL CANCER RESEARCH, Vol.11(24), p.9058S.

Brown, R., Appleton, K., Plumb, J.A., McCormick, C., Lee, C., Barrett, S., Tang, A., Schaetzlein, A., Kaye, S.B., Judson, I., et al. (2005). Pharmacodynamic effects in patients treated with 6 hour infusion of the demethylating agent 5-aza-2 ' deoxycytidine (decitabine)., Presented at AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA. CLINICAL CANCER RESEARCH, Vol.11(24), pp.9071S-9072S.

Nephew, K.P., Huang, T.T., Wei, S.H., Balch, C. & Brown, R. (2005). Epigenetic regulation of transcription in ovarian cancer., Presented at 38th Annual Meeting of the Society-for-the-Study-of-Reproduction, Ctr Rech Biol Reproduct, Quebec City, CANADA. BIOLOGY OF REPRODUCTION, , pp.79-80.

Hall, J.A., Paul, J., Wei, S.H., Huang, T.H. & Brown, R. (2004). Uncovering complex patterns of CPG island methylation associated with clinical outcome in ovarian cancer, Presented at British Cancer Research Meeting 2004, Manchester, ENGLAND. BRITISH JOURNAL OF CANCER, Vol.91, p.S23.

Teodoridis, J.M., Braidwood, L., Hall, J., Vasey, P.A., Strathdee, G. & Brown, R. (2004). Analysis of aberrant CpG-island methylation in stage III and IV ovarian cancer, Presented at British Cancer Research Meeting 2004, Manchester, ENGLAND. BRITISH JOURNAL OF CANCER, Vol.91, p.S53.

Lee, C., Appleton, K., Plumb, J., Kaye, S., Cruickshank, C., Twelves, C., Vasey, P., Judson, I., Brown, R. & Mackay, H., et al. (2004). A phase I trial of the DNA-hypomethylating agent 5-Aza-2 '-Deoxycytidine in combination with carboplatin both given 4 weekly by intravenous injection in patients with advanced solid turnouts., Presented at 40th Annual Meeting of the American-Society-of-Clinical-Oncology, New Orleans, LA. JOURNAL OF CLINICAL ONCOLOGY, Vol.22(14), p.128S.

Strathdee, G.R., Holyoake, T.L., Sim, A. & Brown, R. (2004). The role of DNA methylation of HoxA5, a regulator of haematopoiesis, in progression to myeloid blast crisis in CML., Presented at 46th Annual Meeting of the American-Society-of-Hematology, San Diego, CA. BLOOD, Vol.104(11), pp.565A-566A.

Brown, R. (2003). Pharmacodynamics and epigenomics in clinical trials of epigenetic therapies., Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, BOSTON, MASSACHUSETTS. CLINICAL CANCER RESEARCH, Vol.9(16), p.6275S.

Wei, S.H., Brown, R. & Huang, T.H. (2003). Aberrant DNA methylation in ovarian cancer is there an epigenetic predisposition to drug response?, Presented at Conference on Epigenetic in Cancer Prevention, United States. EPIGENETICS IN CANCER PREVENTION: EARLY DETECTION AND RISK ASSESSMENT, Vol.983, pp.243-250.

Brown, R. (1996). Cellular responses to DNA damage and cisplatin resistance, Presented at 1995 HHMT Forum on Ovarian Cancer, GLASGOW, SCOTLAND. OVARIAN CANCER 4, , pp.205-213.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.